Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 630.00K | 516.00K | 1.60M | 3.45M | 17.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 630.00K | 516.00K | 1.60M | 3.45M | 17.58M |
| Cost of Revenue | 1.54M | 288.00K | 783.00K | 3.03M | 6.92M |
| Gross Profit | -906.00K | 228.00K | 812.00K | 428.00K | 10.66M |
| SG&A Expenses | 3.05M | 3.60M | 3.47M | 3.98M | 5.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.58M | 3.89M | 7.11M | 7.00M | 12.86M |
| Operating Income | -3.95M | -3.37M | -5.52M | -3.55M | 4.72M |
| Income Before Tax | -4.83M | -4.15M | -3.41M | -4.28M | 2.39M |
| Income Tax Expenses | 1.00K | -- | 0.00 | 28.00K | 3.00K |
| Earnings from Continuing Operations | -4.83M | -4.15M | -3.41M | -4.30M | 2.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.83M | -4.15M | -3.41M | -4.30M | 2.39M |
| EBIT | -3.95M | -3.37M | -5.52M | -3.55M | 4.72M |
| EBITDA | -3.94M | -3.34M | -4.47M | -3.19M | 4.96M |
| EPS Basic | -0.32 | -0.29 | -0.25 | -0.32 | 0.20 |
| Normalized Basic EPS | -0.17 | -0.18 | -0.29 | -0.20 | 0.20 |
| EPS Diluted | -0.32 | -0.29 | -0.25 | -0.32 | 0.19 |
| Normalized Diluted EPS | -0.17 | -0.18 | -0.29 | -0.20 | 0.20 |
| Average Basic Shares Outstanding | 15.03M | 14.08M | 13.62M | 13.56M | 12.20M |
| Average Diluted Shares Outstanding | 15.03M | 14.08M | 13.62M | 13.56M | 12.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |